Quantcast

Latest Paclitaxel Stories

2014-02-06 08:29:23

BUFFALO, N.Y., Feb. 6, 2014 /PRNewswire/ -- Kinex Pharmaceuticals and PharmaEssentia Corporation (Taiwan) announced today the execution of a new licensing agreement granting PharmaEssentia exclusive development and commercial rights to Oraxol and Oratecan in Taiwan and Singapore. Kinex will receive an upfront payment, milestones, and royalties. PharmaEssentia has also committed to conducting clinical studies in Taiwan to contribute to the global registration programs for Oraxol...

2014-02-03 12:29:37

Co-inventors of ATM technology joining company as General Manager of the ATM Program, Scientific Advisory Panel member, respectively SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen...

2014-01-28 04:20:52

SEATTLE, Jan. 28, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio(TM) ) as maintenance therapy in ovarian cancer. "Although initial treatment is effective in putting this disease in remission, there is a high relapse rate for patients with ovarian cancer and there...

2014-01-27 13:40:43

Researchers from Warwick Medical School have discovered a critical point of failure in the microscopic transport system that operates inside every cell in the human body. The study, published today in Nature Communications, explains how this tiny 'railway' system is a key target for cancer drugs and, as such, how this new discovery reveals how better drugs might be made. The tracks of this so called 'railway' are tiny tubes, called microtubules, 1000 times thinner than a human hair. The...

2014-01-23 20:22:19

HARBIN, China, Jan. 23, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today issued the following letter to shareholders: DEAR FELLOW SHAREHOLDERS: With the arrival of the Chinese New Year, I would like to take this opportunity to express my appreciation to all shareholders for the trust and...

2014-01-17 20:21:56

MELBOURNE, Australia, Jan. 17, 2014 /PRNewswire/ -- -- Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit -- First Phase III trial in metastatic pancreatic cancer to report three year survival rates[1] -- New standard of care for patients with metastatic pancreatic cancer A leading breast cancer drug, ABRAXANE(®)( )(nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for...

2014-01-13 12:28:03

LONDON, Jan. 13, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Next Generation Stent Technologies (Technical Insights) Milestones in stent technologies achieved through proper funding sources This research service (RS) is a study on the funding prospects in the stent market. Stents are one of the most breakthrough medical devices in the cardiology market. The RS delivers content on the prevalent investor climate in this industry, and attempts to...

2014-01-13 04:20:46

SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has reached an agreement with Novartis to reacquire rights to two anti-cancer compounds -- pixantrone (PIXUVRI(®)) and paclitaxel poliglumex (Opaxio(TM)). Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date. Upon the effective date of termination, CTI will regain...

2013-12-12 10:59:30

98.7 percent are cancer free for at least 3 years A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found. The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related